UB Paderborn / Katalog / Suche / in CDI

037 - Chronic Administration with Cenderitide Goes Beyond Enalapril in Cardiorenal Function and Anti-Remodeling Through Reverse Activation of Gene Pathways in Experimental Heart Failure

Journal of cardiac failure, 2016-08, Vol.22 (8), p.S15-S15

2016

Volltextzugriff (PDF)

092 - MANP: Structural Insights of a Novel GC-A Receptor and cGMP Activator with Cardiorenal Enhancing and Aldosterone Suppressing Actions in Vivo

Journal of cardiac failure, 2017-08, Vol.23 (8), p.S37-S38

2017

Volltextzugriff (PDF)

1116-11 The mineralocorticoid paradox: Profibrotic in vivo in experimental asymptomatic left ventricular dysfunction but antifibrotic in vitro

Journal of the American College of Cardiology, 2004-03, Vol.43 (5), p.A22-A22

2004

Volltextzugriff (PDF)

1160-167 Defining the acute cardiorenal response to high dose nesiritide in severe experimental congestive heart failure

Journal of the American College of Cardiology, 2004-03, Vol.43 (5), p.A520-A520

2004

Volltextzugriff (PDF)

Abstract 11554: Chronic Cenderitide Administration Improves Cardiorenal Function and Remodeling in Experimental Heart Failure

Circulation (New York, N.Y.), 2015-11, Vol.132 (Suppl_3 Suppl 3), p.A11554-A11554

2015

Volltextzugriff (PDF)

Abstract 11947: CRRL269: An Innovative Renal Protective pGC-A Activator for Acute Kidney Injury Treatment

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A11947-A11947

2018

Volltextzugriff (PDF)

Abstract 12085: Gene Expression Profiling for Aorta in Experimental Heart Failure: Differential Regulation of Aortic Remodeling From the Heart

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A12085-A12085

2018

Volltextzugriff (PDF)

Abstract 12636: Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator Which Goes Beyond Carperitide and Nesiritide

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

Abstract 12651: Atrium Fibrosis and Inflammation: Impaired Atrial Natriuretic Peptide System in Experimental Heart Failure

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

Abstract 12979: NPA7: First-in-Class Bispecific GC-A/MasR Activating Peptide That Enhances Cardiorenal Function and Suppresses Renin and Aldosterone In Vivo via Subcutaneous Delivery

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A12979-A12979

2018

Volltextzugriff (PDF)

Abstract 12993: MANP: Novel Natriuretic and Anti-Aldosterone Designer Peptide Without Acute Hyperkalemic Properties: Potassium Actions In Vivo

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A12993-A12993

2018

Volltextzugriff (PDF)

Abstract 15212: Npa7, a First in Class Dual Receptor Activator With Renoprotective Properties

Circulation (New York, N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A15212-A15212

2016

Volltextzugriff (PDF)

Abstract 19094: Antihypertensive Properties of Subcutaneous M-ANP, a Novel Designer Atrial Natriuretic Peptide, in a Canine Model of Chronic Angiotensin-II Induced Hypertension

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

Abstract 2495: Pharmacodynamic Profile of a Novel Chimeric Natriuretic Peptide, CD-NP, as Compared to C-Type Natriuretic Peptide

Circulation (New York, N.Y.), 2007-10, Vol.116 (suppl_16)

2007

Volltextzugriff (PDF)

Abstract 584: Simultaneous Antagonism of the V2 Receptor with Tolvaptan and Activation of the Natriuretic Peptide A-Receptor with B-Type Natriuretic Peptide: A Novel Strategy to Physiologically Enhance Water and Sodium Excretion Without Adversely Affecting Renal Function in a Canine Model of Congestive Heart Failure

Circulation (New York, N.Y.), 2006-10, Vol.114 (suppl_18)

2006

Volltextzugriff (PDF)

Acute NEP/ACE inhibition by omapatrilat is superior to ace inhibition alone in mediating favorable cardiorenal and humoral actions in mild heart failure

Journal of cardiac failure, 1999-09, Vol.5 (3), p.13-13

1999

Volltextzugriff (PDF)

Antinociceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat

European journal of pharmacology, 1985-10, Vol.117 (1), p.81-88

1985

Volltextzugriff (PDF)

B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity

American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Vol.65 (6)

2009

Volltextzugriff (PDF)

B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity

American journal of physiology. Regulatory, integrative and comparative physiology, 2009-06, Vol.296 (6), p.R1744-R1750

2009

Volltextzugriff (PDF)

Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines

BMC pharmacology, 2011-08, Vol.11 (S1), p.P11-P11, Article P11

2011

Volltextzugriff (PDF)

Cardiorenal actions of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide, in the normal dog

BMC pharmacology, 2007-07, Vol.7 (S1), p.P37-P37, Article P37

2007

Volltextzugriff (PDF)

Cardiorenal actions of the new heme-independent direct soluble guanylate cyclase activator BAY 58-2667 in experimental congestive heart failure

Journal of cardiac failure, 2003-10, Vol.9 (5), p.S9-S9

2003

Volltextzugriff (PDF)

Cardiorenal actions of the novel direct soluble guanylate cyclase stimulator BAY 41–2272 in experimental congestive heart failure in comparison to nitroglycerin

Journal of the American College of Cardiology, 2003-03, Vol.41 (6), p.253-254

2003

Volltextzugriff (PDF)

Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure

Circulation (New York, N.Y.), 2003-02, Vol.107 (5), p.686-689

2003

Volltextzugriff (PDF)

Chronic Administration with Cenderitide Goes Beyond Enalapril in Cardiorenal Function and Anti-Remodeling Through Reverse Activation of Gene Pathways in Experimental Heart Failure

Journal of cardiac failure, 2016-08, Vol.22 (8), p.S15-S15

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

037 - Chronic Administration with Cenderitide Goes Beyond Enalapril in Cardiorenal Function and Anti-Remodeling Through Reverse Activation of Gene Pathways in Experimental Heart Failure

092 - MANP: Structural Insights of a Novel GC-A Receptor and cGMP Activator with Cardiorenal Enhancing and Aldosterone Suppressing Actions in Vivo

1116-11 The mineralocorticoid paradox: Profibrotic in vivo in experimental asymptomatic left ventricular dysfunction but antifibrotic in vitro

1160-167 Defining the acute cardiorenal response to high dose nesiritide in severe experimental congestive heart failure

Abstract 11554: Chronic Cenderitide Administration Improves Cardiorenal Function and Remodeling in Experimental Heart Failure

Abstract 11947: CRRL269: An Innovative Renal Protective pGC-A Activator for Acute Kidney Injury Treatment

Abstract 12085: Gene Expression Profiling for Aorta in Experimental Heart Failure: Differential Regulation of Aortic Remodeling From the Heart

Abstract 12636: Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator Which Goes Beyond Carperitide and Nesiritide

Abstract 12651: Atrium Fibrosis and Inflammation: Impaired Atrial Natriuretic Peptide System in Experimental Heart Failure

Abstract 12979: NPA7: First-in-Class Bispecific GC-A/MasR Activating Peptide That Enhances Cardiorenal Function and Suppresses Renin and Aldosterone In Vivo via Subcutaneous Delivery

Abstract 12993: MANP: Novel Natriuretic and Anti-Aldosterone Designer Peptide Without Acute Hyperkalemic Properties: Potassium Actions In Vivo

Abstract 15212: Npa7, a First in Class Dual Receptor Activator With Renoprotective Properties

Abstract 19094: Antihypertensive Properties of Subcutaneous M-ANP, a Novel Designer Atrial Natriuretic Peptide, in a Canine Model of Chronic Angiotensin-II Induced Hypertension

Abstract 2495: Pharmacodynamic Profile of a Novel Chimeric Natriuretic Peptide, CD-NP, as Compared to C-Type Natriuretic Peptide

Acute NEP/ACE inhibition by omapatrilat is superior to ace inhibition alone in mediating favorable cardiorenal and humoral actions in mild heart failure

Antinociceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat

B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity

B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity

Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines

Cardiorenal actions of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide, in the normal dog

Cardiorenal actions of the new heme-independent direct soluble guanylate cyclase activator BAY 58-2667 in experimental congestive heart failure

Cardiorenal actions of the novel direct soluble guanylate cyclase stimulator BAY 41–2272 in experimental congestive heart failure in comparison to nitroglycerin

Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure

Chronic Administration with Cenderitide Goes Beyond Enalapril in Cardiorenal Function and Anti-Remodeling Through Reverse Activation of Gene Pathways in Experimental Heart Failure

Suchergebnisse filtern